Table 1.

Biologicals with potential ocular side effects

I. Inhibitors of epidermal growth factor receptor	1. Inhibitors of tyrosine kinase	a. Gefitinib
		b. Erlotinib
	2. Antibodies against epidermal growth factor receptor	a. Cetuximab
		b. Panitumumab
II. Inhibitors of vascular endothelial growth factor receptor		a. Sunitinib
		b. Pazopanib
		c. Bevacizumab
III. Inhibitors of tumor specific proteins	1. Inhibitors of tyrosine kinase	a. Crizotinib
		b. Imatinib
		c. Vandetanib
	2. Antibodies against tumor specific proteins	a. Ipilimumab
		b. Ganglioside GD2
IV. Estrogen receptor modulator		a. Tamoxifen
V. Interferons